HK1078802A1 - Increasing the bioavailability of alendronate by predose administration alphacalcidol - Google Patents

Increasing the bioavailability of alendronate by predose administration alphacalcidol

Info

Publication number
HK1078802A1
HK1078802A1 HK06101577.3A HK06101577A HK1078802A1 HK 1078802 A1 HK1078802 A1 HK 1078802A1 HK 06101577 A HK06101577 A HK 06101577A HK 1078802 A1 HK1078802 A1 HK 1078802A1
Authority
HK
Hong Kong
Prior art keywords
alphacalcidol
alendronate
bioavailability
increasing
predose
Prior art date
Application number
HK06101577.3A
Other languages
English (en)
Inventor
Vered Rosenberger
Moshe Flashner-Barak
Itzhak E Lerner
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of HK1078802A1 publication Critical patent/HK1078802A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK06101577.3A 2002-12-16 2006-02-06 Increasing the bioavailability of alendronate by predose administration alphacalcidol HK1078802A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43368502P 2002-12-16 2002-12-16
US46020603P 2003-04-02 2003-04-02
PCT/US2003/040174 WO2004058235A2 (fr) 2002-12-16 2003-12-16 Methode pouvant augmenter la biodisponibilite d'alendronate ou autre diphosphonate par administration d'une predose d'un derive de la vitamine d

Publications (1)

Publication Number Publication Date
HK1078802A1 true HK1078802A1 (en) 2006-03-24

Family

ID=32685268

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06101577.3A HK1078802A1 (en) 2002-12-16 2006-02-06 Increasing the bioavailability of alendronate by predose administration alphacalcidol

Country Status (7)

Country Link
JP (3) JP2006514695A (fr)
AU (1) AU2003300984A1 (fr)
DE (1) DE10393906T5 (fr)
GB (1) GB2411116B (fr)
HK (1) HK1078802A1 (fr)
IL (1) IL169127A0 (fr)
WO (1) WO2004058235A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882048C (fr) * 2006-02-03 2020-03-24 Proventiv Therapeutics, Llc Traitement de l'insuffisance et de la deficience de vitamine d avec de la 25-hydroxyvitamine d2 et de la 25-hydroxyvitamine d3
JP2009526840A (ja) * 2006-02-14 2009-07-23 テバ ファーマシューティカル インダストリーズ リミティド 脂肪族アミンポリマーの医薬製剤及びそれらの製造方法
PL2679228T3 (pl) 2006-06-21 2018-07-31 Opko Ireland Global Holdings, Ltd. Terapia z użyciem środka do uzupełniania witaminy D i środka do zastępowania hormonami witaminy D
US20100179110A1 (en) * 2006-12-20 2010-07-15 Mostafa Akbarieh Composition Containing a Bisphosphonic Acid in Combination with Vitamin D
EP2114455A4 (fr) * 2006-12-20 2010-03-17 Mylan Pharmaceuticals Ulc Composition pharmaceutique comprenant un lubrifiant granulé thermofusible
WO2008134518A2 (fr) 2007-04-25 2008-11-06 Cytochroma Inc. Procédés et composés pour une thérapie à base de vitamine d
WO2008134523A1 (fr) 2007-04-25 2008-11-06 Proventiv Therapeutics, Llc Procédé sûr et efficace de traitement et de prévention de l'hyperparathyroïdie secondaire dans les maladies rénales chroniques
ES2403107T3 (es) 2007-04-25 2013-05-14 Cytochroma Inc. Método de tratamiento de insuficiencia y deficiencia de vitamina D
EP3542792B1 (fr) 2007-04-25 2023-06-28 EirGen Pharma Ltd. Libération contrôlée de 25-hydroxyvitamine d
US8962239B2 (en) 2008-04-02 2015-02-24 Opko Renal, Llc Methods useful for vitamin D deficiency and related disorders
HUE048464T2 (hu) 2010-03-29 2020-07-28 Opko Ireland Global Holdings Ltd Módszerek és készítmények mellékpajzsmirigy szintjének csökkentésére
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
CA2957240A1 (fr) 2014-08-07 2016-02-11 Opko Ireland Global Holdings, Ltd. Therapie d'appoint avec de la 25-hydroxyvitamine d
JP7032322B2 (ja) 2016-03-28 2022-03-08 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ治療法
CN109364034B (zh) * 2018-11-26 2021-05-04 正大制药（青岛）有限公司 一种骨化三醇制剂及其制备方法
CN116211818B (zh) * 2023-03-10 2024-04-09 菲洋生物科技(吉林)有限公司 一种含有阿仑膦酸钠的片剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100317935B1 (ko) * 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
EP1416919A1 (fr) * 2001-07-17 2004-05-12 Teva Pharmaceutical Industries Ltd. Formes posologiques pour la liberation gastrique immediate d'un stimulateur de transport du calcium et la liberation gastrique retardee d'un bis-phosphonate

Also Published As

Publication number Publication date
GB0511750D0 (en) 2005-07-20
GB2411116B (en) 2009-04-29
JP2011241221A (ja) 2011-12-01
GB2411116A (en) 2005-08-24
DE10393906T5 (de) 2006-01-12
AU2003300984A1 (en) 2004-07-22
AU2003300984A8 (en) 2004-07-22
JP2014205711A (ja) 2014-10-30
IL169127A0 (en) 2009-02-11
JP2006514695A (ja) 2006-05-11
WO2004058235A2 (fr) 2004-07-15
WO2004058235A3 (fr) 2005-02-24

Similar Documents

Publication Publication Date Title
HK1078802A1 (en) Increasing the bioavailability of alendronate by predose administration alphacalcidol
GB0218625D0 (en) Pharmaceutical compounds
AU2003244650A8 (en) Medicinal compounds
GB0225540D0 (en) Medicinal compounds
GB0204719D0 (en) Medicinal compounds
GB0225535D0 (en) Medicinal compounds
GB0220730D0 (en) Medicinal compounds
GB0225030D0 (en) Medicinal compounds
GB0215775D0 (en) Pharmaceutical compounds
PT1753393T (pt) Procedimento de inoformulação de uma base galénica biocompatível
HK1075936A1 (en) Vaccine for the prevention of malaria
EP1617847A4 (fr) Methodes pour l'administration controlee de composes pharmacologiquement actifs
GB0220740D0 (en) Administration of a system
ITRM20050030A1 (it) Procedimento per l'azionamento sincronizzato di una pluralita' di telecamere elettroniche.
GB0328040D0 (en) Pharmaceutical uses of bisphosphonates
GB0310361D0 (en) Pharmaceutical compound
GB0219897D0 (en) Pharmaceutically active compounds
GB0219893D0 (en) Pharmaceutically active compounds
ZA200204577B (en) Formulations of erytromycin derivatives with improved bioavailability.
GB0212459D0 (en) Pharmaceutical compound
GB0204391D0 (en) Pharmaceutical compound
GB0212462D0 (en) Pharmaceutical compound
GB0219895D0 (en) Pharmaceutically active compounds
GB0207532D0 (en) A novel method for the administration of secretin
GB0208248D0 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20151216